In Vitro: ML355 inhibits PAR-4 induced aggregation and calcium mobilization in human platelets and reduce 12-HETE in β-cells.
In Vivo: ML355 (1.88-30 mg/kg; i.g.; 2 times per day for two days) strongly inhibits the thrombus formation in mice at higher dose compared to WT controls.